These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11677136)

  • 21. UCF116, new inhibitors of farnesyltransferase produced by Streptomyces.
    Hara M; Soga S; Itoh M; Shono K; Eishima J; Mizukami T
    J Antibiot (Tokyo); 2000 Jul; 53(7):720-3. PubMed ID: 10994815
    [No Abstract]   [Full Text] [Related]  

  • 22. Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.
    Curtin ML; Florjancic AS; Cohen J; Gu WZ; Frost DJ; Muchmore SW; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1367-71. PubMed ID: 12657284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones.
    Mitsch A; Böhm M; Wissner P; Sattler I; Schlitzer M
    Bioorg Med Chem; 2002 Aug; 10(8):2657-62. PubMed ID: 12057654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of aralkylsubstituted benzophenones.
    Mitsch A; Wissner P; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2001 Feb; 334(2):40-4. PubMed ID: 11268773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
    Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
    Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
    Mitsch A; Böhm M; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
    Nara S; Tanaka R; Eishima J; Hara M; Takahashi Y; Otaki S; Foglesong RJ; Hughes PF; Turkington S; Kanda Y
    J Med Chem; 2003 Jun; 46(12):2467-73. PubMed ID: 12773050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.
    Li Q; Wang GT; Li T; Gwaltney SL; Woods KW; Claiborne A; Wang X; Gu W; Cohen J; Stoll VS; Hutchins C; Frost D; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5371-6. PubMed ID: 15454229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent, non-thiol inhibitors of farnesyltransferase.
    Breslin MJ; deSolms SJ; Giuliani EA; Stokker GE; Graham SL; Pompliano DL; Mosser SD; Hamilton KA; Hutchinson JH
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3311-6. PubMed ID: 9873725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase.
    Wang GT; Wang X; Wang W; Hasvold LA; Sullivan G; Hutchins CW; O'Conner S; Gentiles R; Sowin T; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2005 Jan; 15(1):153-8. PubMed ID: 15582430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Böhm M; Sattler I
    Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a new class of protein farnesyltransferase inhibitors in the arylthiophene series.
    Lethu S; Ginisty M; Bosc D; Dubois J
    J Med Chem; 2009 Oct; 52(20):6205-8. PubMed ID: 19772293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors.
    Schlitzer M
    Curr Pharm Des; 2002; 8(19):1713-22. PubMed ID: 12171543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.
    Angibaud P; Bourdrez X; End DW; Freyne E; Janicot M; Lezouret P; Ligny Y; Mannens G; Damsch S; Mevellec L; Meyer C; Muller P; Pilatte I; Poncelet V; Roux B; Smets G; Van Dun J; Van Remoortere P; Venet M; Wouters W
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4365-9. PubMed ID: 14643327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.
    Dinsmore CJ; Bogusky MJ; Culberson JC; Bergman JM; Homnick CF; Zartman CB; Mosser SD; Schaber MD; Robinson RG; Koblan KS; Huber HE; Graham SL; Hartman GD; Huff JR; Williams TM
    J Am Chem Soc; 2001 Mar; 123(9):2107-8. PubMed ID: 11456854
    [No Abstract]   [Full Text] [Related]  

  • 36. A new class of highly potent farnesyl diphosphate-competitive inhibitors of farnesyltransferase.
    Aoyama T; Satoh T; Yonemoto M; Shibata J; Nonoshita K; Arai S; Kawakami K; Iwasawa Y; Sano H; Tanaka K; Monden Y; Kodera T; Arakawa H; Suzuki-Takahashi I; Kamei T; Tomimoto K
    J Med Chem; 1998 Jan; 41(2):143-7. PubMed ID: 9457237
    [No Abstract]   [Full Text] [Related]  

  • 37. Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.
    Dinsmore CJ; Bergman JM; Wei DD; Zartman CB; Davide JP; Greenberg IB; Liu D; O'Neill TJ; Gibbs JB; Koblan KS; Kohl NE; Lobell RB; Chen IW; McLoughlin DA; Olah TV; Graham SL; Hartman GD; Williams TM
    Bioorg Med Chem Lett; 2001 Feb; 11(4):537-40. PubMed ID: 11229765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of tripeptidyl farnesyltransferase inhibitors.
    Lee HY; Sohn JH; Kwon BM
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1599-602. PubMed ID: 12039571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.
    Gwaltney SL; O'Connor SJ; Nelson LT; Sullivan GM; Imade H; Wang W; Hasvold L; Li Q; Cohen J; Gu WZ; Tahir SK; Bauch J; Marsh K; Ng SC; Frost DJ; Zhang H; Muchmore S; Jakob CG; Stoll V; Hutchins C; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1363-6. PubMed ID: 12657283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
    Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
    Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.